Skip to content

TG Therapeutics TGTX Warrants Issued With Debt Financing Noncash

Warrants Issued With Debt Financing Noncash at other companies

D-Wave Quantum logo
D-Wave QuantumQBTS
$84.5K
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$408.75K
Joby Aviation logo
Joby AviationJOBY
$21.29M
DraftKings Inc. logo
DraftKings Inc.DKNG
$0-100%
Natera, Inc. logo
Natera, Inc.NTRA
$1.88M
The Kraft Heinz Company logo
The Kraft Heinz CompanyKHC
$0

Other financials

Income statement

See full
Revenue$204.9M+69.6%
Gross profit$171.4M+62.8%
Operating income$34.8M+304%
Net income$19.8M+291%
EPS (diluted)$0.12+300%

Balance sheet

See full
Cash & equivalents$442.2M+235%
Total debt$753.6M+197%
Total equity$583.1M+146%
Total assets$1.5B+133%

Cash flow

See full
Operating cash flow-$17.9M+37.7%
CapEx$51.0K+104%
Free cash flow-$17.9M+37.6%

Valuation

See full
Market cap$8.15B-14.3%
Enterprise value$8.46B-11.1%
P/E17.6×-225×
P/S11.6×-13.0×

Profitability

See full
Gross margin83.1%-4.4pp
Operating margin21.3%+5.9pp
Net margin66%+55.8pp
FCF margin-6,328.4%+4,773pp

Returns & leverage

See full
Return on equity112.6%+92.9pp
Debt / equity1.3×+0.2×
Current ratio5.8×+1.8×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept tgtx:WarrantsIssuedWithDebtFinancingNoncash.

The official record: TG Therapeutics’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's warrants issued with debt financing noncash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TG Therapeutics's warrants issued with debt financing noncash?
TG Therapeutics (TGTX) reported warrants issued with debt financing noncash of $0 in Q4 2025.
What does warrants issued with debt financing noncash mean?
The non-cash value of warrants granted to lenders as part of a debt financing deal.
How do you interpret warrants issued with debt financing noncash?
An increase indicates the use of equity-linked instruments to lower cash interest costs or incentivize lenders, which may lead to future dilution.
How does warrants issued with debt financing noncash compare across companies?
Often seen in growth-stage or distressed companies utilizing complex financing structures.